Warren G H, Mills L, Friedman H
Immunopharmacology. 1979 Jul;1(4):269-76. doi: 10.1016/0162-3109(79)90025-0.
A hydroxythiazolobenzimidazole, a low molecular weight compound, was found to have an immunoenhancing effect on both the in vivo and in vitro antibody response of mouse spleen cells to an optimum immunizing dose of sheep red blood cells. At noncytotoxic concentrations the optimum range of 25 to 50 micrograms per 5 x 19(6) spleen cells was most effective in vitro. Concentrations greater than 100 micrograms per culture were toxic in vitro and reduced cell viability as well as antibody responsiveness. The compound enhanced to an even greater degree the antibody response of spleen cell cultures immunized with suboptimum doses of SRBC. The background PFC response, in the absence of SRBC, also was stimulated by the benzimidazole. These immunoenhancing responses were not related to mitogenic effects, since increased thymidine uptake did not occur when normal mouse spleen cells were incubated with graded doses of the compound. Therefore, the immunostimulatory properties of the compound, both in vivo and in vitro, were not due to mitogenic stimulation of lymphoid cells.
一种低分子量化合物——羟基噻唑苯并咪唑，被发现对小鼠脾细胞在体内和体外针对最佳免疫剂量绵羊红细胞的抗体反应均具有免疫增强作用。在无细胞毒性浓度下，每5×10⁶个脾细胞25至50微克的最佳范围在体外最为有效。每培养物中浓度大于100微克在体外具有毒性，会降低细胞活力以及抗体反应性。该化合物能更显著地增强用次优剂量SRBC免疫的脾细胞培养物的抗体反应。在没有SRBC的情况下，背景PFC反应也受到苯并咪唑的刺激。这些免疫增强反应与促有丝分裂作用无关，因为当正常小鼠脾细胞与分级剂量的该化合物一起孵育时，未出现胸腺嘧啶核苷摄取增加的情况。因此，该化合物在体内和体外的免疫刺激特性并非由于对淋巴细胞的促有丝分裂刺激。
